Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension

Background: New oral prostacyclin therapies and prostacyclin agonists have become available for the treatment of pulmonary arterial hypertension (PAH). However, methods for transitioning between oral, inhaled, and parenteral formulations are not well-established, except in the form of case reports a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Irene Z., Carey, Jessica R., Jacobs, Joshua A., Dechand, John, Sessions, Joshua J., Sorensen, Teshia, Penn, Brittany A., Mayeux, Jennalyn D., Hatton, Nathan D., Ryan, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137736/
https://www.ncbi.nlm.nih.gov/pubmed/32296704
http://dx.doi.org/10.3389/fmed.2020.00081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137736/
https://www.ncbi.nlm.nih.gov/pubmed/32296704
http://dx.doi.org/10.3389/fmed.2020.00081

Ejemplares similares